title: Systematic analysis of design and stratification for phase III trials in first-line advanced non-small cell lung cancer.
abstract: BACKGROUND
  A recent study reviewed phase III trials of first-line advanced non-small cell lung cancer (NSCLC) conducted from 1981 to 2010, and provided trends in the study outcome. However, such trials have never been analyzed in detail for design and stratification factors.
  
  
  METHODS
  Phase III studies of systemic treatment for first-line advanced or metastatic NSCLC published in English literature between 1981 and 2010 were identified. Characteristics, including sample size, number of trials, region, rate of meeting accrual goal, primary endpoint, type of phase III, interim analysis, allocation method, and stratification factors, were determined for each decade.
  
  
  RESULTS
  A total of 162 studies met the criteria. The number of studies and sample size increased over the three decades. The primary endpoint was reported more frequently in recent decades, and non-overall survival endpoints were chosen in European and Asian studies. Interim analysis was conducted more commonly during the 2000s. Allocation method was rarely reported throughout the three decades. The number of stratification factors increased significantly from one in 1980s to three in 2000s. Performance status, stage, and institution were most frequently selected, and at least one of the three factors was used in most of the studies in the 2000s. However, there are many other stratification factors that were used infrequently.
  
  
  CONCLUSIONS
  Despite Consolidated Standards of Reporting Trials guidelines, allocation method has rarely been reported. The choice of stratification factor remains inconsistent across studies.
authors.affiliation: Division of Hematology/Oncology University of Kansas Medical Center Fairway Kansas USA.
authors.forename: Takefumi
authors.initials: T
authors.lastname: Komiya
authors.affiliation: Division of Hematology/Oncology University of Kansas Medical Center Fairway Kansas USA.
authors.forename: Raymond P
authors.initials: RP
authors.lastname: Perez
authors.affiliation: Clinical Trial Office University of Kansas Cancer Center Fairway Kansas USA.
authors.forename: Kirsten D
authors.initials: KD
authors.lastname: Erickson
authors.affiliation: Division of Hematology/Oncology University of Kansas Medical Center Fairway Kansas USA.
authors.forename: Chao H
authors.initials: CH
authors.lastname: Huang
keywords: First‐line; non‐small cell lung cancer; phase III
references.citation: Chin J Integr Med. 2009 Dec;15(6):415-9
references.pmid: 20082245
references.citation: J Clin Oncol. 2013 Sep 20;31(27):3327-34
references.pmid: 23816960
references.citation: J Clin Epidemiol. 1999 Jan;52(1):19-26
references.pmid: 9973070
references.citation: Zhonghua Yi Xue Za Zhi. 2010 Jan 12;90(2):100-2
references.pmid: 20356491
references.citation: Cancer Clin Trials. 1981;4(2):147-53
references.pmid: 6265109
references.citation: Lung Cancer. 1995 Apr;12 Suppl 1:S125-32
references.pmid: 7551920
references.citation: Semin Oncol. 1994 Oct;21(5 Suppl 10):28-33; discussion 33-4
references.pmid: 7973766
references.citation: Anticancer Drugs. 2003 Sep;14(8):639-44
references.pmid: 14501386
references.citation: Semin Oncol. 1988 Dec;15(6 Suppl 7):49-51
references.pmid: 2851179
references.citation: J Natl Cancer Inst. 2000 Feb 16;92(4):321-8
references.pmid: 10675381
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Gastric Cancer. 2012 Apr;15(2):137-43
references.pmid: 21842172
references.citation: N Engl J Med. 2013 Jun 20;368(25):2385-94
references.pmid: 23724913
references.citation: BMJ. 2010 Mar 23;340:c869
references.pmid: 20332511
references.citation: Bull Cancer. 1996 May;83(5):385-94
references.pmid: 8680091
references.citation: Lung Cancer. 2001 Dec;34 Suppl 4:S65-9
references.pmid: 11742706
references.citation: J Clin Oncol. 2014 May 10;32(14):1407-11
references.pmid: 24590634
references.citation: J Natl Cancer Inst. 1999 Jan 6;91(1):66-72
references.pmid: 9890172
references.citation: BMJ. 1995 Oct 7;311(7010):899-909
references.pmid: 7580546
references.citation: Semin Oncol. 1988 Dec;15(6 Suppl 7):42-5
references.pmid: 2851177
references.citation: J Clin Oncol. 2001 Aug 1;19(15):3539-46
references.pmid: 11481361
references.citation: N Engl J Med. 2009 Sep 3;361(10):947-57
references.pmid: 19692680
references.citation: Cancer. 2005 Dec 15;104(12):2766-74
references.pmid: 16288485
references.citation: Anticancer Res. 2008 Nov-Dec;28(6B):3997-4002
references.pmid: 19192663
references.citation: Ann Oncol. 2007 Oct;18(10):1666-72
references.pmid: 17660495